Among other things, we talked about President Trump’s “most-favored nations” policy on drug pricing and why Regeneron is the ...

The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...

More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...

President Donald Trump on Thursday announced the outlines of a health care plan he wants Congress to take up as Republicans ...

María Corina Machado, Venezuela’s opposition leader and last year’s Nobel Peace Prize winner, presented her prize to ...

Quick Read Direxion Biotech Bull 3X (LABU) doubled over the past year by delivering three times the daily biotech index ...

Measles, which was declared to be eliminated in 2000 in the United States, has seen a resurgence, with more than 2,000 cases ...

Even with breakthroughs, treatment for advanced squamous cell carcinoma is more complex. Patients often need more than one treatment. Many patients with this advanced cancer are cared for by a team of ...

ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million -- KPL-38 ...